for Journals by Title or ISSN
for Articles by Keywords
The Medical Letter    [5 followers]  Follow    
  Full-text available via subscription Subscription journal
     ISSN (Print) 0025-732X - ISSN (Online) 1523-2859
     Published by The Medical Letter, Inc Homepage  [1 journal]   [SJR: 0.161]   [H-I: 15]
  • Inhaled Loxapine (Adasuve) for Acute Agitation - The Medical Letter
    • Authors: admin
      Abstract: April 14, 2014 - The FDA has approved an inhalation powder formulation of loxapine (Adasuve – Teva), a first-generation antipsychotic long available in an oral formulation, for treatment of acute agitation related to schizophrenia or bipolar I disorder in adults. Adasuve is the first inhaled drug to be approved for this indication.
  • Ibrutinib (Imbruvica) for Chronic Lymphocytic Leukemia - The Medical
    • Authors: admin
      Abstract: April 14, 2014 - The FDA has approved ibrutinib (eye broo' ti nib; Imbruvica – Janssen/Pharmacyclics), an oral kinase inhibitor, for second-line treatment of chronic lymphocytic leukemia (CLL). It is the first kinase inhibitor to be approved for CLL. Ibrutinib was approved earlier for second-line treatment of mantle cell lymphoma, a rare form of B-cell non-Hodgkins lymphoma.
  • Anoro Ellipta: An Inhaled Umeclidinium/Vilanterol Combination for COPD -
           The Medical Letter
    • Authors: admin
      Abstract: April 14, 2014 - The FDA has approved an inhaled fixed-dose combination of the long-acting anticholinergic umeclidinium (ue mek" li din' ee um) and the long-acting beta2-adrenergic agonist (LABA) vilanterol (Anoro Ellipta – GSK/Theravance) for once-daily maintenance treatment of chronic obstructive pulmonary disease (COPD). Anoro Ellipta is the first product available in the US that combines two long-acting bronchodilators in a single delivery device.
  • Drugs for Peptic Ulcer Disease and GERD - Treatment Guidelines
    • Authors: admin
      Abstract: April 1, 2014 - H2-RECEPTOR ANTAGONISTS (H2RAs) — Currently available H2RAs are listed in Table 1. These drugs inhibit the action of histamine at the H2-receptor of the gastric parietal cell, decreasing basal acid secretion and, to a lesser degree, food-stimulated acid secretion. All H2RAs are about equally effective for treatment of PUD and GERD. H2RAs are faster acting than PPIs in relieving symptoms of dyspepsia or GERD, but they are not as effective as PPIs in relieving symptoms or in healing erosive esophagitis. Repeated administration of H2RAs leads to pharmacologic tolerance and has...
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
About JournalTOCs
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-2014